Taiga Biotechnologies Inc
Business Identifier: Therapies from stem cells
Public Profile:
Taiga Biotechnologies, Inc. is a privately held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions. Each of the company's core programs derives from Taiga's proprietary technology platform for conditionally immortalized adult hematopoetic stem cells (HSCs). The company’s initial focus includes the discovery and development of fully human therapeutic monoclonal antibodies against difficult protein targets, an immune response enhancer for improving vaccination strategies for infectious diseases and cancer, and the development of a universal donor blood stem cell line for clinical use.

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Generation Of Hiv Resistant Cells From Protein Transduced Hematopoetic Stem Cell
Molecular Based Strategies To Generate Protective Immune Responses To Hiv-1
Large-Scale Generation Of Human Red Blood Cells For Transfusion Therapy
Rapid Generation Of Human Therapuetic Antibodies Against Influenza